Gutenberg Open Science: Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7840

Full metadata record

DC Field	Value	Language
dc.contributor.author	Krusche, Benjamin	-
dc.contributor.author	Arend, Joachim	-
dc.contributor.author	Efferth, Thomas	-
dc.date.accessioned	2022-10-05T08:32:47Z	-
dc.date.available	2022-10-05T08:32:47Z	-
dc.date.issued	2013	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/7855	-
dc.description.abstract	Inhibition of angiogenesis represents one major strategy of cancer chemotherapy. In the present investigation, we investigated the synergism of artesunate and captopril to inhibit angiogenesis. Artesunate is an antimalarial derivative of artemisinin from the Chinese medicinal plant, Artemisia annua L., which also reveals profound anticancer activity in vitro and in vivo. Captopril is an angiotensin I-converting (ACE) inhibitor, which is well established in Western academic medicine. Both compounds inhibited migration of human umbilical vein endothelial cells (HUVECs) in vitro. The combination of both drugs resulted in synergistically inhibited migration. Whereas artesunate inhibited HUVEC growth in the XTT assay, captopril did not, indicating independent modes of action. We established a chorioallantoic membrane (CAM) assay of quail embryos (Coturnix coturnix L.) and a computer-based evaluation routine for quantitative studies on vascularization processes in vivo. Artesunate and captopril inhibited blood vessel formation and growth. For the first time, we demonstrated that both drugs revealed synergistic effects when combined. These results may also have clinical impact, since cardiovascular diseases and cancer frequently occur together in older cancer patients. Therefore, comorbid patients may take advantage, if they take captopril to treat cardiovascular symptoms and artesunate to treat cancer.	en_GB
dc.description.sponsorship	DFG, Open Access-Publizieren Universität Mainz / Universitätsmedizin	de
dc.language.iso	eng	de
dc.rights	CC BY	*
dc.rights.uri	https://creativecommons.org/licenses/by/3.0/	*
dc.subject.ddc	570 Biowissenschaften	de_DE
dc.subject.ddc	570 Life sciences	en_GB
dc.title	Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-7840	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 09 Chemie, Pharmazie u. Geowissensch.	de
jgu.organisation.number	7950	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Evidence-based complementary and alternative medicine	de
jgu.journal.volume	2013	de
jgu.pages.alternative	Art. 454783	de
jgu.publisher.year	2013	-
jgu.publisher.name	Hindawi	de
jgu.publisher.place	New York, NY	de
jgu.publisher.uri	http://dx.doi.org/10.1155/2013/454783	de
jgu.publisher.issn	1741-4288	de
jgu.publisher.issn	1741-427X	de
jgu.organisation.place	Mainz	-
jgu.identifier.pmid	24223058	-
jgu.subject.ddccode	570	de
opus.date.modified	2018-07-31T10:05:01Z	-
opus.subject.dfgcode	00-000	-
opus.organisation.string	FB 09: Chemie, Pharmazie und Geowissenschaften: Institut für Pharmazie	de_DE
opus.identifier.opusid	24635	-
opus.importsource	pubmed	-
opus.institute.number	0908	-
opus.metadataonly	false	-
opus.type.contenttype	Keine	de_DE
opus.type.contenttype	None	en_EN
opus.affiliated	Arend, Joachim	-
opus.affiliated	Efferth, Thomas	-
jgu.publisher.doi	10.1155/2013/454783	de
jgu.organisation.ror	https://ror.org/023b0x485	-
Appears in collections:	DFG-OA-Publizieren (2012 - 2017)

Files in This Item:

	File	Description	Size	Format
	synergistic_inhibition_of_ang-20221005103458805.pdf		721.22 kB	Adobe PDF	View/Open

Show simple item record